Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...